Advertisement

Clinical Drug Investigation

, Volume 26, Issue 2, pp 55–62 | Cite as

Methotrexate and Hepatic Toxicity in Rheumatoid Arthritis and Psoriatic Arthritis

  • Lindsey Tilling
  • Sue Townsend
  • Joel David
Original Research Article

Abstract

Background: We set out in this study to demonstrate the adverse effect profile of methotrexate when used in the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in a district general hospital population, and to investigate the effect of alcohol consumption in these patients.

Methods: A prospective evaluation of 550 RA patients and 69 PsA patients was undertaken, controlling for confounding factors. Systematically randomised patients were further analysed regarding alcohol consumption. A transaminase level of three times the upper limit of normal on two or more occasions was taken to indicate hepatic injury.

Results: Gastrointestinal disturbance was the predominant adverse effect in RA patients (9.8%); hepatic disturbance was the most frequent in PsA patients (14.5%). Both groups had hepatic enzyme elevation; PsA patients were at significantly greater risk of elevated transaminases than RA patients (14.5% vs 7.5%, respectively, χ2 = 4.017). Alcohol consumption did not correlate with hepatic injury (mean 5.15 vs 6.6 alcohol units/week consumed by RA and PsA patients, respectively).

Conclusion: Our data show methotrexate-treated PsA patients have a higher incidence of hepatotoxicity compared with methotrexate-treated patients with RA. It is proposed that psoriatic patients may be inherently more susceptible to methotrexate hepatotoxicity than are rheumatoid patients.

Keywords

Rheumatoid Arthritis Methotrexate Rheumatoid Arthritis Patient Psoriatic Arthritis Auranofin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors thank Dr Lucy Estcourt for her contribution to this manuscript.

No funding was received for this study. No benefits from commercial sources that could lead to potential conflicts of interests were received for work reported on in the study.

References

  1. 1.
    Bertino J. The mechanism of action of the folate antagonists in man. Cancer Res 1963; 23: 1286–306PubMedGoogle Scholar
  2. 2.
    Weinblatt JE, Coblyn JS, Fox DA, et al. Efficacy of low dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818–22PubMedCrossRefGoogle Scholar
  3. 3.
    Williams HJ, Willkens RF, Samuelson Jr CO, et al. Comparison of low dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985; 28: 721–30PubMedCrossRefGoogle Scholar
  4. 4.
    Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity: effects of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221: 276–82Google Scholar
  5. 5.
    Espinoza LR, Zakraou L, Carman G, et al. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 1992; 19: 872–7PubMedGoogle Scholar
  6. 6.
    Kersley GD. Amethopterin (methotrexate) in connective tissue disease, psoriasis and polyarthritis. Ann Rheum Dis 1968; 27: 64–6PubMedCrossRefGoogle Scholar
  7. 7.
    Black RL, O’Brien WM, Van Scott EJ, et al. Methotrexate therapy in psoriatic arthritis: a double blind study on 21 patients. JAMA 1964; 189: 743–7PubMedCrossRefGoogle Scholar
  8. 8.
    Weinblatt ME, Kaplan H, Germain BF, et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis: a thirty-six week, double blind trial. Arthritis Rheum 1990; 33: 330–8PubMedCrossRefGoogle Scholar
  9. 9.
    Jeurissen MEC, Boerbooms AMT, van de Putte LBA, et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: a forty-eight week randomized, double blind trial. Arthritis Rheum 1991; 34: 961–72PubMedCrossRefGoogle Scholar
  10. 10.
    Rau R, Herborn G, Karger T, et al. A double blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis. J Rheumatol 1991; 18: 328–33PubMedGoogle Scholar
  11. 11.
    Cohen S, Rutstein J, Luggen M, et al. Comparison of safety and efficacy of cyclosporin A and methotrexate in refractory rheumatoid arthritis: a randomized, multicentered placebo-controlled trial [abstract]. Arthritis Rheum 1993; 36: S56Google Scholar
  12. 12.
    Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in rheumatoid arthritis: a five year prospective multicenter trial. Arthritis Rheum 1994; 37: 1492–8PubMedCrossRefGoogle Scholar
  13. 13.
    Alarcon GS, Kremer JM, Macaluso M, et al. METHOTREXATE-lung toxicity in RA: a multicenter case control study [abstract]. Arthritis Rheum 1995; 38: S205CrossRefGoogle Scholar
  14. 14.
    Kamel OW, Van de Rijn M, Weiss LM, et al. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328: 1317–21PubMedCrossRefGoogle Scholar
  15. 15.
    Shiroky JB, Frost A, Skelton JD, et al. Complications of immunosuppression associated with weekly low dose methotrexate. J Rheumatol 1991; 18: 1172–5PubMedGoogle Scholar
  16. 16.
    Liote F, Pertuiset E, Cochand-Priollet B, et al. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis: role of Epstein-Barr virus infection. J Rheumatol 1995; 22: 1174–8PubMedGoogle Scholar
  17. 17.
    Colsky J, Greenspan EM, Warren TN. Hepatic fibrosis in children with acute leukaemia after therapy with folic acid antagonists. AMA Arch Pathol 1955; 59: 198–206PubMedGoogle Scholar
  18. 18.
    Epstein EH, Craft JD. Cirrhosis following methotrexate administration for psoriasis. Arch Dermatol 1969; 100: 531–4PubMedCrossRefGoogle Scholar
  19. 19.
    Muller SA, Farrow GM, Martalook DL. Cirrhosis caused by methotrexate in the treatment of psoriasis. Arch Dermatol 1969; 100: 523–30PubMedCrossRefGoogle Scholar
  20. 20.
    Phillips CA, Cera PJ, Mangan TF, et al. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol 1992; 19: 229–33PubMedGoogle Scholar
  21. 21.
    Erickson AR, Reddy V, Vogelgesang SA, et al. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum 1995; 38(8): 1115–9PubMedCrossRefGoogle Scholar
  22. 22.
    Phillips CA, Cera PJ, Mangan TF, et al. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol 1992; 19: 229–33PubMedGoogle Scholar
  23. 23.
    Zachariae H, Kragballe K, Sφgaard H. Methotrexate-induced liver cirrhosis: studies including serial liver biopsies during continued treatment. Br J Dermatol 1980; 102: 407–12PubMedCrossRefGoogle Scholar
  24. 24.
    Kremer JM, Tolman K, Samowitz W. Long-term prospective sequential liver biopsies in patients with rheumatoid arthritis on weekly oral methotrexate [abstract]. Arthritis Rheum 1990; 33 Suppl.: 40CrossRefGoogle Scholar
  25. 25.
    Arnett FC, Edworthy JM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 Mar; 31 (3): 315–24Google Scholar
  26. 26.
    Michet JM. Psoriatic arthritis. In: Kelley WN, Harris ED Jr, Ruddy S, et al., editors. Textbook of rheumatology. Philadelphia (PA): WB Saunders, 1993: 974–84Google Scholar
  27. 27.
    Coleiro B, Mallia C. Toxicity profile of methotrexate in rheumatoid arthritis: a preliminary survey. Adv Exp Med Biol 1999; 455: 359–65PubMedCrossRefGoogle Scholar
  28. 28.
    Ohosone Y, Okano Y, Kameda H, et al. Toxicity of low-dose methotrexate in rheumatoid arthritis —clinical characteristics in patients with methotrexate induced pancytopaenia and interstitial pneumonitis. Ryumachi 1997 Feb; 37(1): 16–23PubMedGoogle Scholar
  29. 29.
    Haustein VF, Rytter M. Methotrexate in psoriasis: 26 years’ experience with low dose in long-term treatment. J Eur Acad Dermatol Venereol 2000 Sep; 14(5): 382–8PubMedCrossRefGoogle Scholar
  30. 30.
    Hoekstra M, Van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003 May; 62(5): 423–6PubMedCrossRefGoogle Scholar
  31. 31.
    Ujfalussy J, Koo E, Sesztak M, et al. Termination of disease-modifying drugs in rheumatoid arthritis and in psoriatic arthritis: a comparative study of 270 cases. Z Rheumatol 2003 Apr; 62(2): 155–60PubMedCrossRefGoogle Scholar
  32. 32.
    van Dooren-Greebe RJ, Kuijpers ALA, Mulder J. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130: 204–10PubMedCrossRefGoogle Scholar
  33. 33.
    Boffa MJ, Chalmers RJG, Haboubi NY, et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995; 133: 774–8PubMedCrossRefGoogle Scholar
  34. 34.
    Weinstein G, Roenigk H, Maibach H, et al. Psoriasis-liver-methotrexate interactions [abstract]. Arch Dermatol 1973; 108: 36–42CrossRefGoogle Scholar
  35. 35.
    Rabinovitz M, Van Thiel DH. Hepatotoxicity of nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1992; 87: 1696–704PubMedGoogle Scholar
  36. 36.
    Bridges SL, Alarcon GS, Koopman WJ. Methotrexate-induced liver abnormalities in rheumatoid arthritis. J Rheumatol 1989; 16: 1180–3PubMedGoogle Scholar
  37. 37.
    Kaplan MM. Methotrexate hepatotoxicity and the premature reporting of Mark Twain’s death: both greatly exaggerated. Hepatology 1990; 12: 784–6PubMedCrossRefGoogle Scholar
  38. 38.
    Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology 2004 Mar; 43(3): 267–71PubMedCrossRefGoogle Scholar
  39. 39.
    Markin RS, Donovan JP, Shaw BW, et al. Fulminant hepatic failure after methotrexate and PUVA therapy for psoriasis. J Clin Gastroenterol 1993; 17: 311–3PubMedCrossRefGoogle Scholar
  40. 40.
    Roenigk Jr HH, Bergfeld WF, St Jacques R, et al. Hepatotoxicity of methotrexate. Arch Dermatol 1971; 103: 250–61PubMedCrossRefGoogle Scholar
  41. 41.
    Nyfors A, Svegaard A. The relation of HLA antigens to liver histology in methotrexate-treated psoriatics. Acta Derm Venereol 1976; 56: 235–8PubMedGoogle Scholar
  42. 42.
    Almeyda J, Barnardo D, Baker H, et al. Structural and functional abnormalities of the liver in psoriasis before and during methotrexate therapy. Br J Dermatol 1972; 87: 623–31PubMedCrossRefGoogle Scholar
  43. 43.
    O’Connor GT, Olmstead EM, Zug K, et al. Detection of hepatotoxicity associated with methotrexate therapy for psoriasis. Arch Dermatol 1989; 125: 1209–17PubMedCrossRefGoogle Scholar
  44. 44.
    Brick JE, Moreland LW, Al-Kawas F, et al. Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients. Semin Arthritis Rheum 1989; 19: 31–44PubMedCrossRefGoogle Scholar
  45. 45.
    Tishler M, Caspi D, Yaron M. Long-term experience with low dose methotrexate in rheumatoid arthritis. Rheumatol Int 1993; 13: 103–6PubMedCrossRefGoogle Scholar
  46. 46.
    Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84 month update. Arthritis Rheum 1992; 35: 129–37PubMedCrossRefGoogle Scholar
  47. 47.
    Walker AM, Funch D, Dreyer NA, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993; 36: 329–35PubMedCrossRefGoogle Scholar
  48. 48.
    Bjorkman DJ, Hammond EH, Lee RG, et al. Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 1988; 31: 1465–72PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Lindsey Tilling
    • 1
  • Sue Townsend
    • 1
  • Joel David
    • 1
  1. 1.Department of RheumatologyRoyal Berkshire and Battle Hospitals NHS TrustReadingUK

Personalised recommendations